Drug:
Reaction: EXPOSURE VIA SKIN CONTACT
20260101 - 20261231
No. 601 - 700
| No. | safetyreportid |
occurcountry |
patientonsetage |
patientsex 1:M 2:F |
|---|---|---|---|---|
Adverse reaction |
||||
Drug (openfda.generic_name, medicinalproduct) |
||||
| 601 | 26406355 |
US |
68 | 1 |
Accidental exposure to product, Exposure via skin contact, Drug dose omission by device, Product communication issue, Device difficult to use, |
||||
EVOLOCUMAB, |
||||
| 602 | 26406464 |
US |
2 | |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 603 | 26406487 |
US |
59 | 2 |
Inappropriate schedule of product administration, Exposure via skin contact, Accidental exposure to product, |
||||
INSULIN GLARGINE, |
||||
| 604 | 26395972 |
US |
62 | 2 |
Exposure via skin contact, Wrong technique in device usage process, Accidental exposure to product, Incorrect dose administered, Product storage error, Product complaint, |
||||
BELIMUMAB, |
||||
| 605 | 26396342 |
US |
2 | |
Accidental exposure to product, Exposure via skin contact, Device difficult to use, |
||||
EVOLOCUMAB, EVOLOCUMAB, EVOLOCUMAB, |
||||
| 606 | 26396491 |
US |
68 | 1 |
Device difficult to use, Injury associated with device, Injection site pain, Wrong technique in product usage process, Accidental exposure to product, Exposure via skin contact, Drug dose omission by device, |
||||
ETANERCEPT, |
||||
| 607 | 26397296 |
US |
68 | 2 |
Exposure via skin contact, Wrong technique in device usage process, Accidental exposure to product, Product dose omission issue, |
||||
MEPOLIZUMAB, |
||||
| 608 | 26398869 |
US |
47 | 2 |
Eye disorder, Injection site pain, Injection site urticaria, Accidental exposure to product, Exposure via skin contact, |
||||
ETANERCEPT, ETANERCEPT, |
||||
| 609 | 26399974 |
US |
2 | |
Product design issue, Product delivery mechanism issue, Circumstance or information capable of leading to medication error, Product knowledge deficit, Product use complaint, Exposure via skin contact, Accidental exposure to product, Product packaging quantity issue, Inappropriate schedule of product administration, Product use issue, |
||||
PERFLUOROHEXYLOCTANE, PERFLUOROHEXYLOCTANE, PERFLUOROHEXYLOCTANE, |
||||
| 610 | 26400085 |
US |
2 | |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 611 | 26400103 |
US |
2 | |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 612 | 26400111 |
US |
83 | 2 |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 613 | 26400169 |
US |
2 | |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 614 | 26400284 |
US |
88 | 2 |
Accidental exposure to product, Exposure via skin contact, |
||||
INSULIN GLARGINE AND LIXISENATIDE, |
||||
| 615 | 26400305 |
US |
||
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 616 | 26400336 |
US |
38 | 2 |
Injection site pain, Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 617 | 26400337 |
US |
51 | 2 |
Exposure via skin contact, Injection site pain, Urticaria, Accidental exposure to product, |
||||
DUPILUMAB, HYDROXYZINE HYDROCHLORIDE, HYDROXYZINE, HYDROXYZINE HYDROCHLORIDE ORAL, PRAZOSIN HYDROCHLORIDE, PREDNISONE, SERTRALINE HYDROCHLORIDE, |
||||
| 618 | 26400357 |
US |
2 | |
Exposure via skin contact, Accidental exposure to product, |
||||
DUPILUMAB, |
||||
| 619 | 26400362 |
US |
60 | 1 |
Injection site swelling, Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 620 | 26400432 |
US |
73 | 2 |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 621 | 26400459 |
US |
47 | 1 |
Injection site pain, Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 622 | 26400478 |
US |
76 | 1 |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 623 | 26400574 |
US |
2 | |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 624 | 26391658 |
US |
2 | |
Injection site swelling, Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 625 | 26391667 |
US |
57 | 2 |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, OMEPRAZOLE, OMEPRAZOLE MAGNESIUM, LISINOPRIL, CARIPRAZINE, METFORMIN, METFORMIN ER 500 MG, METFORMIN ER 750 MG, FLUTICASONE PROPIONATE, FLUTICASONE PROPIONATE NASAL, DULOXETINE HYDROCHLORIDE, DULOXETINE, MONTELUKAST SODIUM, MONTELUKAST, EZETIMIBE, |
||||
| 626 | 26391678 |
US |
1 | |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 627 | 26391878 |
US |
68 | 1 |
Device deployment issue, Accidental exposure to product, Exposure via skin contact, |
||||
ABATACEPT, METHOTREXATE, METHOTREXATE SODIUM, |
||||
| 628 | 26392150 |
US |
83 | 2 |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 629 | 26392152 |
US |
73 | 2 |
Off label use, Accidental exposure to product, Exposure via skin contact, |
||||
INSULIN GLARGINE, INSULIN GLARGINE, |
||||
| 630 | 26392190 |
US |
1 | |
Accidental exposure to product, Exposure via skin contact, |
||||
INSULIN GLARGINE, |
||||
| 631 | 26392196 |
US |
84 | 1 |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 632 | 26392573 |
US |
62 | 1 |
Exposure via skin contact, Wrong technique in device usage process, Accidental exposure to product, |
||||
EVOLOCUMAB, |
||||
| 633 | 26392823 |
US |
76 | 1 |
Accidental exposure to product, Incorrect dose administered by device, Exposure via skin contact, |
||||
EVOLOCUMAB, EVOLOCUMAB, EVOLOCUMAB, |
||||
| 634 | 26393905 |
US |
2 | |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 635 | 26393958 |
US |
||
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 636 | 26393963 |
US |
||
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 637 | 26393984 |
US |
1 | |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 638 | 26394012 |
US |
58 | 1 |
Injection site pain, Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 639 | 26394035 |
US |
76 | 1 |
Accidental exposure to product, Exposure via skin contact, |
||||
INSULIN GLARGINE, |
||||
| 640 | 26394382 |
US |
84 | 2 |
Accidental exposure to product, Exposure via skin contact, |
||||
ADALIMUMAB-ATTO, |
||||
| 641 | 26394447 |
US |
2 | |
Accidental exposure to product, Exposure via skin contact, |
||||
SARILUMAB, |
||||
| 642 | 26394545 |
US |
74 | 2 |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, ATORVASTATIN CALCIUM, ATORVASTATIN CALCIUM, FILM COATED, MONTELUKAST SODIUM, ALBUTEROL SULFATE, OLMESARTAN MEDOXOMIL, FLUTICASONE FUROATE, UMECLIDINIUM BROMIDE AND VILANTEROL TRIFENATATE, |
||||
| 643 | 26394586 |
US |
75 | 1 |
Wrong technique in product usage process, Accidental exposure to product, Exposure via skin contact, |
||||
EVOLOCUMAB, |
||||
| 644 | 26394885 |
US |
||
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 645 | 26394893 |
US |
60 | 1 |
Injection site swelling, Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 646 | 26394894 |
US |
18 | 2 |
Accidental exposure to product, Exposure via skin contact, Product use in unapproved indication, |
||||
DUPILUMAB, |
||||
| 647 | 26395159 |
US |
68 | 2 |
Injection site indentation, Accidental exposure to product, Exposure via skin contact, Device difficult to use, Drug dose omission by device, Arthritis, |
||||
EVOLOCUMAB, EVOLOCUMAB, |
||||
| 648 | 26395281 |
US |
2 | |
Accidental exposure to product, Exposure via skin contact, |
||||
EVOLOCUMAB, |
||||
| 649 | 26395303 |
US |
24 | 2 |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 650 | 26390596 |
US |
58 | 2 |
Exposure via skin contact, Accidental exposure to product, Product dose omission issue, Product complaint, |
||||
MEPOLIZUMAB, |
||||
| 651 | 26390671 |
US |
54 | 1 |
Injection site pain, Injection site swelling, Exposure via skin contact, Accidental exposure to product, |
||||
DUPILUMAB, |
||||
| 652 | 26390734 |
US |
2 | |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 653 | 26390793 |
US |
59 | 2 |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, FLUTICASONE FUROATE, UMECLIDINIUM BROMIDE AND VILANTEROL TRIFENATATE, MONTELUKAST SODIUM, BUDESONIDE, ALBUTEROL SULFATE, ALBUTEROL, |
||||
| 654 | 26390913 |
US |
79 | 1 |
Injection site pain, Lack of injection site rotation, Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 655 | 26391198 |
US |
31 | 2 |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 656 | 26391436 |
US |
69 | 2 |
Injection site injury, Accidental exposure to product, Exposure via skin contact, |
||||
EVOLOCUMAB, |
||||
| 657 | 26389527 |
US |
1 | |
Urticaria, Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 658 | 26389664 |
US |
23 | 2 |
Pruritus, Dry skin, Accidental exposure to product, Exposure via skin contact, Drug ineffective, |
||||
DUPILUMAB, |
||||
| 659 | 26389801 |
US |
81 | 1 |
Device use error, Exposure via skin contact, Accidental exposure to product, Drug dose omission by device, |
||||
EVOLOCUMAB, |
||||
| 660 | 26389822 |
US |
40 | 1 |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 661 | 26389849 |
US |
63 | 2 |
Spinal operation, Migraine, Device difficult to use, Exposure via skin contact, Accidental exposure to product, |
||||
ERENUMAB-AOOE, ERENUMAB-AOOE, |
||||
| 662 | 26389876 |
US |
69 | 2 |
Injection site urticaria, Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 663 | 26389921 |
US |
71 | 2 |
Exposure via skin contact, Accidental exposure to product, Product complaint, |
||||
MEPOLIZUMAB, |
||||
| 664 | 26389948 |
US |
74 | 1 |
Accidental exposure to product, Exposure via skin contact, |
||||
INSULIN GLARGINE, |
||||
| 665 | 26389951 |
US |
1 | |
Injection site pain, Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 666 | 26390070 |
US |
58 | 2 |
Accidental exposure to product, Exposure via skin contact, |
||||
INSULIN GLARGINE, |
||||
| 667 | 26390151 |
US |
12 | 1 |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 668 | 26390202 |
US |
2 | |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, MEPOLIZUMAB, |
||||
| 669 | 26384837 |
US |
81 | 2 |
Cataract, Hip fracture, Fall, Headache, Vision blurred, Visual acuity reduced, Injection site urticaria, Eczema, Rash, Product dose omission issue, Decreased appetite, Dyspnoea exertional, Nausea, Abdominal pain upper, Gastrointestinal disorder, Fatigue, Pruritus, Skin burning sensation, Dizziness, Eye irritation, Swelling face, Urticaria, Eye pruritus, Off label use, Accidental exposure to product, Exposure via skin contact, Therapeutic product effective for unapproved indication, |
||||
DUPILUMAB, DUPILUMAB, DUPILUMAB, BUPROPION HYDROCHLORIDE, |
||||
| 670 | 26385077 |
US |
77 | 2 |
Injection site pain, Exposure via skin contact, Dyskinesia, Wrong technique in device usage process, Underdose, Accidental exposure to product, |
||||
MEPOLIZUMAB, |
||||
| 671 | 26385434 |
US |
79 | 1 |
Exposure via skin contact, Device use error, Underdose, Accidental exposure to product, |
||||
MEPOLIZUMAB, |
||||
| 672 | 26385772 |
US |
41 | 1 |
Device difficult to use, Accidental exposure to product, Exposure via skin contact, |
||||
ETANERCEPT, |
||||
| 673 | 26386358 |
US |
38 | 2 |
Injection site pain, Exposure via skin contact, Wrong technique in device usage process, Accidental exposure to product, Product dose omission issue, Product complaint, |
||||
MEPOLIZUMAB, |
||||
| 674 | 26387718 |
US |
81 | 2 |
Accidental exposure to product, Exposure via skin contact, |
||||
EVOLOCUMAB, |
||||
| 675 | 26388500 |
US |
2 | |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 676 | 26388513 |
US |
||
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 677 | 26388525 |
US |
7 | 1 |
Skin laceration, Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 678 | 26388535 |
US |
49 | 2 |
Dizziness, Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 679 | 26388558 |
US |
2 | |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 680 | 26388575 |
US |
||
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 681 | 26388621 |
US |
71 | 1 |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 682 | 26388629 |
US |
2 | |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 683 | 26388640 |
US |
2 | |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 684 | 26388646 |
US |
2 | |
Injection site haemorrhage, Dry skin, Skin burning sensation, Accidental exposure to product, Exposure via skin contact, Injection site bruising, |
||||
DUPILUMAB, FINASTERIDE, MELOXICAM, ROSUVASTATIN CALCIUM, MINOXIDIL, METHOTREXATE, METHOTREXATE SODIUM, ERGOCALCIFEROL, CLOBETASOL PROPIONATE, CLOBETASOL PROPIONATE OINTMENT USP, 0.05%, |
||||
| 685 | 26388662 |
US |
72 | 2 |
Injection site pain, Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, ALBUTEROL SULFATE, ALBUTEROL, BUDESONIDE AND FORMOTEROL FUMARATE DIHYDRATE, TIOTROPIUM BROMIDE, |
||||
| 686 | 26388752 |
US |
57 | 1 |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 687 | 26388886 |
US |
||
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 688 | 26388913 |
US |
15 | 1 |
Urticaria, Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 689 | 26388997 |
US |
2 | |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 690 | 26389006 |
US |
19 | 2 |
Injection site discolouration, Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 691 | 26389037 |
US |
7 | 1 |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 692 | 26389047 |
US |
55 | 2 |
Accidental exposure to product, Exposure via skin contact, Incorrect dose administered, |
||||
DUPILUMAB, MOMETASONE FUROATE AND FORMOTEROL FUMARATE DIHYDRATE, |
||||
| 693 | 26389201 |
US |
||
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 694 | 26389205 |
US |
67 | 1 |
Accidental exposure to product, Exposure via skin contact, |
||||
INSULIN GLARGINE, |
||||
| 695 | 26389238 |
US |
5 | 1 |
Chapped lips, Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 696 | 26389256 |
US |
83 | 1 |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 697 | 26389274 |
US |
34 | 2 |
Accidental exposure to product, Exposure via skin contact, Product use in unapproved indication, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 698 | 26389342 |
US |
48 | 1 |
Injection site pain, Increased appetite, Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 699 | 26389360 |
US |
2 | |
Injection site pain, Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 700 | 26389501 |
US |
2 | |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
disclaimer
Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. We may limit or otherwise restrict your access to the API in line with our Terms of Service.
terms
license
last_updated
2026-04-28